| Patents for A61P 21 - Drugs for disorders of the muscular or neuromuscular system (23,287) |
|---|
| 03/21/2002 | US20020035262 7-hetero-bicyclo[2.2.1]-heptanes |
| 03/21/2002 | US20020035151 Calcium formate for use as a dietary supplement |
| 03/21/2002 | US20020035147 Nervous system, psychological disorders |
| 03/21/2002 | US20020035122 8-azabicyclo[3.2.1]oct-2-ene and -octane derivatives |
| 03/21/2002 | US20020035117 Theophylline and 3-isobutyl-1-methylxanthine based N-7 substituted derivatives displaying inhibitory activities on type five phosphodiesterase |
| 03/21/2002 | US20020035102 Azetidine derivatives, their preparation and medicaments containing them |
| 03/21/2002 | US20020035094 Substituted pyridine compounds and methods of use |
| 03/21/2002 | US20020034513 MHC complexes and uses thereof |
| 03/21/2002 | CA2422774A1 Remedies for amyotrophic lateral sclerosis |
| 03/21/2002 | CA2422586A1 Methods and compositions relating to hydrogen peroxide and superoxide production by antibodies |
| 03/21/2002 | CA2422137A1 Tetrahydroquinoline compounds |
| 03/21/2002 | CA2422076A1 Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination |
| 03/21/2002 | CA2422044A1 Nitrogen-containing compounds and their use as glycine transport inhibitors |
| 03/21/2002 | CA2421786A1 Compounds and methods for inhibiting alpha-1 beta-1 integrins |
| 03/21/2002 | CA2421279A1 2-amino-2-alkyl-3 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors |
| 03/21/2002 | CA2420450A1 2-amino-2-alkyl-3 hexenoic and hexynoic acid derivatives useful as nitric oxide synthase inhibitors |
| 03/21/2002 | CA2419219A1 Chemokine receptor binding heterocyclic compounds |
| 03/21/2002 | CA2418720A1 Caspase inhibitors and uses thereof |
| 03/20/2002 | EP1188754A1 Substituted pyrazole compounds |
| 03/20/2002 | EP1188442A2 Cinnamomi and poria composition, method to prepare the same and uses thereof |
| 03/20/2002 | EP1187843A1 Angiogenic proteins and uses thereof |
| 03/20/2002 | EP1187827A1 Antiviral agents |
| 03/19/2002 | US6358987 For therapy and prophylaxis of rheumatoid arthritis, osteoarthritis, osteopenias such as osteoporosis, periodontitis, gingivitis, corneal epidermal or gastric ulceration, and tumour metastasis, invasion and growth |
| 03/19/2002 | US6358944 Methods and compositions for treating generalized anxiety disorder |
| 03/19/2002 | US6358706 Nucleotide sequences coding membrane protein; for use in treatment of epilepsy, schizophrenia, depression, sleep, stress, muscle, endocrine, respiratory, fertility, contraceptive, cardiovascular disorders and atherosclerosis |
| 03/14/2002 | WO2002020736A2 Proteases |
| 03/14/2002 | WO2002020485A1 Spiroheterocyclic nitriles useful as reversible inhibitors of cysteine proteases |
| 03/14/2002 | WO2002020465A2 Gamma-ketoacid dipeptides as inhibitors of caspase-3 |
| 03/14/2002 | WO2002019967A2 Substituted hydrazine derivatives |
| 03/14/2002 | WO2001093890A3 Botulinum toxin implant |
| 03/14/2002 | WO2001093827A3 Neurotoxin implant |
| 03/14/2002 | WO2001070734A3 Beta-amino acid derivatives as inhibitors of matrix metalloproteases and tnf-alpha |
| 03/14/2002 | WO2001070673A3 CYCLIC β-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEASES AND TNF-$g(a) |
| 03/14/2002 | WO2001066081A3 Pharmaceutical preparations containing saccharose fatty acid esters for controlling the release of active ingredients |
| 03/14/2002 | WO2001058852A3 (r)-2-aryl-propionamides, useful in the inhibition of il-8-induced chemiotaxis of neutrophils |
| 03/14/2002 | WO2001051512A3 Human and parasite orphan receptor proteins |
| 03/14/2002 | WO2000065028A9 TGF-α POLYPEPTIDES, FUNCTIONAL FRAGMENTS AND METHODS OF USE THEREFOR |
| 03/14/2002 | US20020032228 Inhibiting adenylate cyclase with a composition comprising an amount of a heterocycle-containing compound (e.g., imidazole, Celebrex or DuP-697) effective to inhibit the generation of cAMP from ATP |
| 03/14/2002 | US20020032225 Treatment of inflammation, inflammatory and immunological diseases, insulin resistance, hyperlipidemia, coronary artery disease, cancer and multiple sclerosis. |
| 03/14/2002 | US20020032224 Treatment of inflammatory diseases and other diseases involving elevated levels of cytokines, as well as central nervous system disorders |
| 03/14/2002 | US20020031792 Complexing with monoclonal antibodies |
| 03/14/2002 | US20020031480 Aerosolizing a hydrofluoroalkane (HFA)/THC composition to provide droplets respirable by a lung of a patient, and administering; inhalers; treating pain, cachexia, migraines, nausea,muscle spasticity |
| 03/14/2002 | CA2422198A1 Substituted hydrazine derivatives |
| 03/14/2002 | CA2421922A1 Proteases |
| 03/14/2002 | CA2421172A1 Gamma-ketoacid dipeptides as inhibitors of caspase-3 |
| 03/14/2002 | CA2417177A1 Spiroheterocyclic nitriles useful as reversible inhibitors of cysteine proteases |
| 03/13/2002 | EP1185694A1 49 human secreted proteins |
| 03/13/2002 | EP1185649A2 The myostatin gene promoter and inhibition of activation thereof |
| 03/13/2002 | EP1185543A1 50 human secreted proteins |
| 03/13/2002 | EP1185532A1 Peroxynitrite decomposition catalysts and methods of use thereof |
| 03/13/2002 | EP1185306A1 Use of viral vectors and charged molecules for gene therapy |
| 03/13/2002 | EP1185304A2 Conjugates comprising cytokines and nucleic acids for treating proliferating cells |
| 03/13/2002 | EP1185302A2 Specifically targeted catalytic antagonists and uses thereof |
| 03/13/2002 | EP1185291A2 Therapeutic agent comprising a botulinum neurotoxin |
| 03/13/2002 | EP1185285A1 49 human secreted proteins |
| 03/13/2002 | EP1185284A1 47 human secreted proteins |
| 03/13/2002 | EP1185272A2 Novel use of 1-[4-(5-cyanoindol-3yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine and its physiological acceptable salts |
| 03/13/2002 | EP0936908B1 Anticonvulsant derivatives useful in treating amyotrophic lateral sclerosis (als) |
| 03/13/2002 | CN1340098A Astrocytes, their preparation and use thereof |
| 03/13/2002 | CN1340044A Nervinolin derivatives |
| 03/13/2002 | CN1339955A Gels formed by the interaction of poly(aldehyde) with various sabstances |
| 03/12/2002 | US6355805 β3-adrenergic receptor agonists |
| 03/12/2002 | US6355690 Remedy for CAG repeat expansion diseases |
| 03/12/2002 | US6355479 Insect polypeptide for use in the treatment of autoimmune diseases, allergies and cancer |
| 03/12/2002 | US6355265 Over-coated chewing gum formulations |
| 03/07/2002 | WO2002018623A2 Methods and reagents for protease inhibition |
| 03/07/2002 | WO2002018575A2 Genes expressed in the cell cycle |
| 03/07/2002 | WO2002018554A2 Isolated human drug-metabolizing proteins, nucleic acid moleculesand uses thereof |
| 03/07/2002 | WO2002018444A2 Erbb4 antagonists |
| 03/07/2002 | WO2002018395A1 Phosphate derivatives as immunoregulatory agents |
| 03/07/2002 | WO2002018346A1 Pyrazole derivatives and their use as protein kinase inhibitors |
| 03/07/2002 | WO2002018340A1 GEM-SUBSTITUTED α v β 3 INTEGRIN ANTAGONISTS |
| 03/07/2002 | WO2002017967A1 Method of increasing testosterone and related steroid concentrations in women |
| 03/07/2002 | WO2002017944A1 Use of a composition comprising an extract of pollen for the treatment of hormonally-related disorders |
| 03/07/2002 | WO2002017943A1 Use of a composition comprising an extract of pollen for the treatment of disease-related weight gain |
| 03/07/2002 | WO2002017942A1 Use of a composition comprising an extract of pollen for the treatment of irritability |
| 03/07/2002 | WO2002017941A1 Use of a composition comprising an extract of pollen for the treatment of edema |
| 03/07/2002 | WO2002017940A1 Use of a composition comprising an extract of pollen for the treatment of dysphoria |
| 03/07/2002 | WO2002017927A1 Method for treating erectile dysfunction and increasing libido in men |
| 03/07/2002 | WO2002017914A2 Fused pyrrolocarbazoles against inflammation |
| 03/07/2002 | WO2001093911A3 Macromolecular drug complexes and compositions containing the same |
| 03/07/2002 | WO2001077100A3 Benzoamide piperidine compounds as substance p antagonists |
| 03/07/2002 | WO2001068033A3 Il-8 receptor antagonists |
| 03/07/2002 | WO2001062236A3 New drug combinations comprising a norepinephrine reuptake inhibitor and an antimuscarinic agent |
| 03/07/2002 | WO2001057233A3 Methods and materials relating to preadipocyte factor-1-like (pref-1-like) polypeptides and polynucleotides |
| 03/07/2002 | WO2001057022A3 Pyrazole compositions useful as inhibitors of erk |
| 03/07/2002 | WO2001055692A3 Neurosteroids as markers for alzheimer's disease |
| 03/07/2002 | WO2001055219A3 scsCNTFR/NNT-1 FUSION PROTEIN |
| 03/07/2002 | US20020028814 Aza compounds, pharmaceutical compositions and methods of use |
| 03/07/2002 | US20020028244 Biodegradable neurotoxin implant |
| 03/07/2002 | US20020028216 Controlled release implantable drug delivery system composed of a plurality of botulinum toxin-incorporating polymeric microspheres. |
| 03/07/2002 | US20020028207 Complexes of alpha (2) macroglobulin and antigenic molecules for immunotherapy |
| 03/07/2002 | CA2746787A1 Method of increasing testosterone and related steroid concentrations in women |
| 03/07/2002 | CA2424146A1 Use of a composition comprising an extract of pollen for the treatment of hormonally-related disorders |
| 03/07/2002 | CA2424026A1 Use of a composition comprising an extract of pollen for the treatment of dysphoria |
| 03/07/2002 | CA2424011A1 Use of a composition comprising an extract of pollen for the treatment of disease-related weight gain |
| 03/07/2002 | CA2421893A1 Phosphate derivatives as immunoregulatory agents |
| 03/07/2002 | CA2420906A1 Use of a composition comprising an extract of pollen for the treatment of edema |
| 03/07/2002 | CA2420832A1 Methods and reagents for protease inhibition |
| 03/07/2002 | CA2420823A1 Use of a composition comprising an extract of pollen for the treatment of irritability |